Transfusion Medicine and Hemostasis, 2nd Edition

Key Features

• Updated content covers new coagulation tests, cellular therapies, and quality control issues
• Easy to use, with focused, well-defined chapters in a standardized format throughout
• Offers quick "cross-reference" lists at the end of each chapter
• Includes lists of common abbreviations and indexes that cross reference diagnostic, clinical and therapeutic commonalities

Description

The second edition of Transfusion Medicine and Hemostasis continues to be the only "pocket-size" quick reference for pathology residents and transfusion medicine fellows. It covers all topics in blood banking, transfusion medicine, and clinical and laboratory based coagulation. Short, focused chapters, organized by multiple hierarchical headings, are supplemented with up to 10 suggested reading citations. This single reference covers essentially all the topics required to meet the goals and objectives of a major program in transfusion medicine and clinical coagulation.

New chapters in the coagulation testing section reflect the development of new tests available and their incorporation into clinical practice. Coverage includes essential updates on the importance of new cellular therapies, peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in the understanding of molecular testing and pathogen reduction in two separate quality control chapters (one for blood centers and one for hospitals).

Readership

Residents and fellows in hematology, transfusion medicine, pathology, and anesthesiology; practicing physicians in hematology, transfusion medicine, pathology, and anethesiology.

Transfusion Medicine and Hemostasis, 2nd Edition

TABLE OF CONTENTS:

I. Blood Banking and Transfusion Medicine

A. Introduction

1. BLOOD BANKING AND TRANSFUSION MEDICINE – THE FIELD, THE DISCIPLINE AND THE INDUSTRY
CHRISTOPHER D. HILLYER, MD

2. A BRIEF HISTORY OF BLOOD TRANSFUSION
ALFRED J. GRINDON, MD

3. INTRODUCTION TO QUALITY SYSTEMS and QUALITY MANAGEMENT JIMMIE L. EVANS AND CHRISTOPHER D. HILLYER, MD

B. Blood Banking

4. THE ROLE OF THE PHYSICIAN IN THE BLOOD CENTER
CHRISTOPHER D. HILLYER, MD

a. Donation process

5. BLOOD DONOR, DONATION PROCESS AND TECHNICAL ASPECTS OF BLOOD COLLECTION
KRISTA L. HILLYER, MD

6. APHERESIS BLOOD COMPONENT COLLECTIONS
KRISTA L. HILLYER, MD

7. RECIPIENT-SPECIFIC BLOOD DONATION
KRISTA L. HILLYER, MD

8. ADVERSE DONOR REACTIONS
KRISTA L. HILLYER, MD

b. Component manufacturing

9. COMPONENT PREPARATION AND MANUFACTURING
COURTNEY E. GREENE AND CHRISTOPHER D. HILLYER, MD

c. Donor testing

10. SEROLOGIC TESTING OF DONOR PRODUCTS
KRISTA L. HILLYER, MD

11. OVERVIEW OF INFECTIOUS DISEASE TESTING
CHRISTOPHER D. HILLYER, MD

12. HIV SCREENING OF DONOR PRODUCTS
KRISTA L. HILLYER, MD

13. HEPATITIS B SCREENING OF DONOR PRODUCT
KRISTA L. HILLYER, MD

14. HEPATITIS C SCREENING OF DONOR PRODUCT
KRISTA L. HILLYER, MD

15. WNV SCREENING OF DONOR PRODUCT
KRISTA L. HILLYER, MD

16. SYPHILIS, HTLV, AND CHAGAS TESTING OF DONOR PRODUCT
CHELSEA A. SHEPPARD, MD AND KRISTA L. HILLYER, MD

17. BACTERIAL DETECTION METHODS
BETH H. SHAZ, MD

C. Transfusion Medicine

18. THE ROLE OF THE TRANSFUSION SERVICE PHYSICIAN
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

a. Testing

19. PRETRANSFUSION TESTING
BETH H. SHAZ, MD

20. ANTIBODY IDENTIFICATION
BETH H. SHAZ, MD

21. DIRECT ANTIGLOBULIN TEST
BETH H. SHAZ, MD

b. Blood groups

22. ABO AND H BLOOD GROUP SYSTEMS
BETH H. SHAZ, MD

23. RH BLOOD GROUP SYSTEM
BETH H. SHAZ, MD

24. KELL AND KIDD BLOOD GROUP SYSTEMS
BETH H. SHAZ, MD

25. MNS AND DUFFY BLOOD GROUP SYSTEMS
BETH H. SHAZ, MD JOHN D. ROBACK, MD, PhD

26. LEWIS,I , AND P BLOOD GROUP SYSTEMS
BETH H. SHAZ, MD

27. OTHER BLOOD GROUP SYSTEMS, COLLECTIONS, AND ANTIGENS
BETH H. SHAZ, MD

c. Blood products

28. RED BLOOD CELLS AND RELATED PRODUCTS
CHRISTOPHER D. HILLYER, MD

29. PLASMA PRODUCTS
CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD

30. PLATELET PRODUCTS
BETH H. SHAZ, MD

31. CRYOPRECIPITATE
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

32. GRANULOCYTE PRODUCTS
CHRISTOPHER D. HILLYER, MD AND LAWRENCE B. FIALCOW, DO
33. ALBUMIN AND RELATED PRODUCTS
ANNE M. WINKLER, MD AND BETH H. SHAZ, MD

34. HUMAN IMMUNOGLOBULIN PREPARATIONS
BETH H. SHAZ, MD

35. RH IMMUNE GLOBULIN
BETH H. SHAZ, MD

d.Product modifications

36. IRRADIATION OF BLOOD PRODUCTS
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

37. LEUKOREDUCTION OF BLOOD PRODUCTS
JAMES C. ZIMRING, MD, PhD

38. CMV- SAFE BLOOD PRODUCTS
JOHN D. ROBACK, MD, PhD

39. FROZEN BLOOD PRODUCTS
CASSSANDRA D. JOSEPHSON, MD and BETH H. SHAZ, MD

40. WASHED BLOOD PRODUCTS
CASSSANDRA D. JOSEPHSON, MD and BETH H. SHAZ, MD

41. VOLUME REDUCED BLOOD PRODUCTS
CASSSANDRA D. JOSEPHSON, MD

e. Specific clinical settings

42. NEONATAL AND PEDIATRIC TRANSFUSION MEDICINE
JEANNE E. HENDRICKSON, MD AND CASSSANDRA D. JOSEPHSON, MD

43. PERINATAL TRANSFUSION MEDICINE
BETH H. SHAZ, MD

44. AUTOIMMUNE HEMOLYTIC ANEMIAS
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

45. TRANSFUSION MANAGEMENT IN PATIENTS WITH HEMOGLOBINOPATHIES
BETH H. SHAZ, MD

46. TRANSFUSION OF PATIENTS UNDERGOING HPC AND SOLID ORGAN TRANSPLANTATION
JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD

47. TRANSFUSION OF HIV POSITIVE PATIENTS
JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD

48. TRANSFUSION MANAGEMENT IN PATIENTS WHO REFUSE BLOOD TRANSFUSION
JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD

49. PLATELET TRANSFUSION REFRACTORY PATIENTS
JEANNE E. HENDRICKSON, MD and JOHN D. ROBACK, MD, PhD

50. MASSIVE TRANSFUSION
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

51. PERIOPERATIVE BLOOD MANAGEMENT
BETH H. SHAZ, MD

f. Transfusion reactions

52. ADVERSE EVENTS AND OUTCOMES FOLLOWING TRANSFUSION: AN OVERVIEW
CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD

53. FEBRILE NON-HEMOLYTIC TRANSFUSION REACTIONS
CASSSANDRA D. JOSEPHSON, MD

54. ALLERGIC, ANAPHYLACTOID AND ANAPHYLATIC REACTIONS
BETH H. SHAZ, MD

55. ACUTE HEMOLYTIC TRANSFUSION REACTIONS
CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD

56. DELAYED HEMOLYTIC TRANSFUSION REACTIONS
CASSSANDRA D. JOSEPHSON, MD

57. TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD
JEANNE E. HENDRICKSON, MD and CHRISTOPHER D. HILLYER, MD

58. TRANSFUSION RELATED ACUTE LUNG INJURY
JEANNE E. HENDRICKSON, MD and CHRISTOPHER D. HILLYER, MD

59. SEPTIC TRANSFUSION REACTIONS
CASSSANDRA D. JOSEPHSON, MD

60. METABOLIC, HYPOTENSIVE AND OTHER ACUTE REACTIONS AND COMPLICATIONS
BETH H. SHAZ, MD

61. POST TRANSFUSION PURPURA
ALFRED J. GRINDON

62. TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

63. MICROCHIMERISM
BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD

64. TRANSFUSION RELATED IMMUNOMODULATION
JAMES C. ZIMRING, MD, PhD

65. IRON OVERLOAD
CASSSANDRA D. JOSEPHSON, MD

66. TRANSFUSION TRANSMITTED DISEASES
BETH H. SHAZ, MD

g. Therapeutic apheresis and phlebotomy

67. OVERVIEW TO THERAPEUTIC APHERESIS
BETH H. SHAZ, MD

68. THERAPEUTIC PLASMA EXCHANGE
BETH H. SHAZ, MD

69. THERAPEUTIC ERYTHROCYTAPHERESIS
BETH H. SHAZ, MD

70. THERAPEUTIC THROMBOCYTAPHERESIS
BETH H. SHAZ, MD

71. THERAPEUTIC LEUKOCYTAPHERESIS
BETH H. SHAZ, MD

72. EXTRACORPOREAL PHOTOPHERESIS
MARY DORROW, MD JEANNE E. HENDRICKSON, MD, and JOHN D. ROBACK, MD, PhD

73. LDL APHERESIS
BETH H. SHAZ, MD

74. IMMUNOABSORPTION
BETH H. SHAZ, MD

75. THERAPEUTIC PHLEBOTOMY
LAWRENCE B. FIALCOW, DO and BETH H. SHAZ, MD

h. Cellular therapy and tissue banking

76. HPC PRODUCTS
JOHN D. ROBACK, MD, PhD and ELLIE HAMILTON

77. TISSUE BANKING in the HOSPITAL SETTING
CASSSANDRA D. JOSEPHSON, MD

II. Coagulation

A. Introduction

78. AN OVERVIEW OF THE COAGULATION SYSTEM
THOMAS C. ABSHIRE, MD and SHAWN JOBE, MD, PhD

B. Clinical coagulation

79. APPROACH TO THE BLEEDING PATIENT
THOMAS C. ABSHIRE, MD

a. Neonatal thrombocytopenia

80. CONGENITAL THROMBOCYTOPENIA
SHAWN JOBE, MD, PhD

81. NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
CAROLYN BENNETT, MD

82. ACQUIRED NEONATAL THROMBOCYTOPENIA
CAROLYN BENNETT, MD

b. inherited platelet function disorders

83. BERNARD-SOULIER SYNDROME AND OTHER GPIB-IX-V RELATED RECEPTOR DEFECTS
SHAWN JOBE, MD, PhD

84. GLANZMANN'S THROMBOCYTOPENIA
SHAWN JOBE, MD, PhD

85. PLATELET STORAGE GRANULE DEFECTS
SHAWN JOBE, MD, PhD

86. FAILURE TO RELEASE AND ASPIRIN-LIKE DEFECTS
SHAWN JOBE, MD, PhD

c. Immune thrombocytopenia

87. ACUTE (CHILDHOOD) IMMUNE THROMBOCYTOPENIC PURPURA CAROLYN BENNETT, MD

88. CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
CAROLYN BENNETT, MD

89. DRUG INDUCED THROMBOCYTOPENIA
CAROLYN BENNETT, MD

90. HEPARIN INDUCED THROMBOCYTOPENIA
CHRISTINE KEMPTON, MD

91. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
MICHAEL BRIONES, DO

d. Immune mediated coagulopathies

92. HEMOLYTIC UREMIC SYNDROME
MICHAEL BRIONES, DO

93. THROMBOTIC THROMBOCYTOPENIC PURPURA
CHRISTINE KEMPTON, MD

94. ANTIPHOSPHOLIPID ANTIBODY SYNDROME
MICHAEL BRIONES, DO

e. congenital bleeding disorders

95. VON WILLEBRAND DISEASE
THOMAS C. ABSHIRE, MD

96. HEMOPHILIA A
AMY DUNN, MD

97. HEMOPHILIA B
AMY DUNN, MD

98. CONGENITAL DISORDERS OF FIBRINOGEN
SHANNON MEEKS, MD

99. FACTOR XIII, D á2-ANTIPLASMIN, AND PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCIES
SHANNON MEEKS, MD

100. FACTOR XI DEFICIENCY
THOMAS C. ABSHIRE, MD

101. FACTOR VII DEFICIENCY
SHANNON MEEKS, MD

102. FACTOR II, FACTOR V, AND FACTOR X DEFICIENCIES
SHANNON MEEKS, MD

f. acquired bleeding disorders

103. BLEEDING DISORDERS IN PREGNANCY
CHRISTINE KEMPTON, MD

104. VASCULAR BLEEDING DISORDERS
MICHAEL BRIONES, DO

105. BLEEDING RISKS WITH LIVER DISEASE
THOMAS C. ABSHIRE, MD

106. BLEEDING RISKS WITH VITAMIN K DEFICIENCY
THOMAS C. ABSHIRE, MD

107. BLEEDING RISKS WITH CARDIAC DISEASE
THOMAS C. ABSHIRE, MD

108. BLEEDING RISKS WITH RENAL DISEASE
THOMAS C. ABSHIRE, MD

109. BLEEDING IN CANCER
MICHAEL BRIONES, DO

110. DISSEMINATED INTRAVASCULAR COAGULOPATHY
AMY DUNN, MD

111. ACQUIRED COAGULATION FACTOR INHIBITORS
CHRISTINE KEMPTON, MD

C. Laboratory testing of coagulation

a. Introduction

112. INTRODUCTION TO COAGULATION TESTING
JAMES C. ZIMRING, MD, PhD

b. Screening tests

113. PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME
JAMES C. ZIMRING, MD, PhD

114. PLATELET COUNT
JAMES C. ZIMRING, MD, PhD

115. GLOBAL TESTS FOR PRIMARY HEMOSTASIS
CONNIE H. MILLER Ph.D.

c. Laboraty assessment of platelet disorders

116. PLATELET AGGREGATION STUDIES
CONNIE H. MILLER Ph.D.

117. LABORATORY DIAGNOSIS OF GENETIC PLATELET FUNCTION DEFECTS
CONNIE H. MILLER Ph.D.

118. LABORATORY DIAGNOSIS OF ACQUIRED PLATELET FUNCTION DEFECTS
CONNIE H. MILLER Ph.D.

119. LABORATORY DIAGNOSIS IMMUNE THROMBOCYTOPENIC PURPURA
CAROLYN BENNETT, MD

120. ADAMTS 13 ASSAYS
CHRISTINE KEMPTON, MD

121. LABORATORY TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA
ANNE M. WINKLER, MD AND JAMES C. ZIMRING, MD, PHD

d. Laboratoy assessment of VWD

122. MOLECULAR BIOLOGY OF VON WILLEBRAND DISEASE
CONNIE H. MILLER Ph.D.

123. DIAGNOSIS OF INHERITED VON WILLEBRAND DISEASE
Connie H. Miller Ph.D.

124. LABORATORY DIAGNOSIS OF ACQUIRED VWD
CONNIE H. MILLER Ph.D.

125. LABORATORY ASSESSMENT OF TREATMENT OF VWD
CONNIE H. MILLER Ph.D.

e. Laboratoy assessment of coagulation factor disorders

126. SPECIFIC FACTOR ASSAYS
CONNIE H. MILLER Ph.D.

127. MIXING STUDIES
CONNIE H. MILLER Ph.D.

128. SPECIFIC FACTOR INHIBITORS
Connie H. Miller Ph.D.

f. Laboratoy assessment of fibrinogen and fibrinolysis

129. LABORATORY DIAGNOSIS OF DYSFIBRINOGENEMIA AND AFIBRINOGENEMIA
THOMAS C. ABSHIRE, MD

130. LABORATORY ASSESSMENT OF FIBRINOLYSIS
THOMAS C. ABSHIRE, MD

g. Tests for hypercoagulable state

131. GENERAL OVERVIEW OF THE HYPERCOAGULABLE STATE
MICHAEL BRIONES, DO

132. ANTITHROMBIN TESTING
JAMES C. ZIMRING, MD, PhD

133. PROTEINS C, S, AND Z
JAMES C. ZIMRING, MD, PhD

134. ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN
ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD

135. PROTHROMBIN GENE MUTATION
ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD

136. HYPERHOMOCYSTENEMIA
JAMES C. ZIMRING, MD, PhD

137. LUPUS ANTICOAGULANT AND ANTIPHOSPHOLIPID ANTIBODIES
MICHAEL BRIONES, DO

138. LIPOPROTEIN (A)
ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD

139. FACTOR LEVEL ABNORMALITIES ASSOCIATED WITH THROMBOSIS
JAMES C. ZIMRING, MD, PhD

h. Tests for activation of the coagulation system

140. LABORATORY MANAGEMENT OF DIC
THOMAS C. ABSHIRE, MD

i. Laboratoy support for anticoagulation

141. HEPARIN MONITORING
ANNE WINKLER MD AND JAMES C. ZIMRING, MD, PhD

142. WARFARIN MONITORING
ANNE M. WINKLER M.D.

D. Coagulation factor products

143. PROTHROMBIN COMPLEX CONCENTRATES
CHRISTINE KEMPTON, MD

144. VON WILLEBRAND FACTOR PRODUCTS
THOMAS C. ABSHIRE, MD

145. FACTOR VIII CONCENTRATES
AMY DUNN, MD

146. FACTOR IX CONCENTRATES
AMY DUNN, MD

147. FACTOR VII CONCENTRATE
CHRISTINE KEMPTON, MD

148. ANTITHROMBIN PRODUCTS
MICHAEL BRIONES, DO

149. PROTEIN C PRODUCTS
MICHAEL BRIONES, DO